Roche's CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-stain biomarkers aid in detection of cervical precancer and may reduce the number of women who undergo unnecessary colposcopy procedures while allowing earlier intervention for those who are at higher risk of developing cervical cancer. This recognition follows the American Society for Colposcopy and Cervical Pathology (ASCCP)'s recent ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum. Shares of TG Therapeutics (NASDAQ: TGTX ) made new 52-week highs this w ...

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members This is the first time that any antiviral used in the treatment of a respiratory viral illness has demonstrated a transmission reduction benefit in a global phase III study Reducing the spread of infection in the household could help limit transmission within communities and societies, easing the burden of both seasonal and pandemic influenza on healthcare systems Basel, 1 ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest healthcare news straight to your inbox. Subscribe here to receive future editions. Good afternoon! Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly? The answer isn't clear yet. We need to see more data from longer and larger clinical tri ...

Core Viewpoint - The article compares Roche Holding AG (RHHBY) and AbbVie (ABBV) to determine which stock is more attractive to value investors [1] Group 1: Zacks Rank and Earnings Outlook - Roche Holding AG has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while AbbVie has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank emphasizes companies with positive earnings estimate revisions, suggesting RHHBY is likely experiencing a more favorable earnings outlook [3] Group 2: Valuation Metrics - RHHBY has a forward P/E ratio of 14.51, compared to ABBV's forward P/E of 18.01, indicating RHHBY may be undervalued [5] - The PEG ratio for RHHBY is 2.26, while ABBV's PEG ratio is 2.67, suggesting RHHBY has a better expected EPS growth relative to its valuation [5] - RHHBY's P/B ratio is 7.93, significantly lower than ABBV's P/B of 50.69, further indicating RHHBY's relative undervaluation [6] Group 3: Value Grades - Based on various valuation metrics, RHHBY holds a Value grade of B, while ABBV has a Value grade of C, making RHHBY a more attractive option for value investors [6]

OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's office This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally OCREVUS ZUNOVO™ offers people with multiple sclerosis (MS) more options to access treatment based on their individual needs Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug A ...

Roche (RHHBY) announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab). The SC formulation was approved under the brand name Tecentriq Hybreza (atezolizumab and hyaluronidasetqjs). Per Roche, the approval makes Tecentriq Hybreza the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy in the United States. Image Source: Zacks Investment Research Year to date, Roche's shares have gained 8% compared with the industry's 25.4% ...

OCREVUS ZUNOVO™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints SAN DIEGO, Sept. 13, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) with Halozyme's ENHANZE® drug delivery technology for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PP ...

Roche (RHHBY) is set to enter the competitive continuous glucose monitor (CGM) market in Europe following the CE mark approval of its Accu-Chek Smartguide in July. The Swiss pharmaceutical company plans to launch the device in the Netherlands, Switzerland and Germany, targeting adults with Type 1 or Type 2 diabetes. Sérgio Moreiras, Roche's international business leader for continuous monitoring, shared details about the launch at the European Association for the Study of Diabetes annual meeting in Madrid. ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track. Weight-management treatments are all the rage lately. According to Morgan Stanley, combined sales of injections that curb appetites and promote weight loss could reach an estimated $105 billion by 2030. Viking Therapeutics (VKTX 3.25%) is still a clinical-stage drugmaker that's developing an anti-obesity candidate called VK2735 that appears competitive with a similar drug the U. ...